A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
December 30, 2013
End Date
June 22, 2015
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
December 30, 2013
End Date
June 22, 2015